Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
22 hedge funds and large institutions have $1.93M invested in Carisma Therapeutics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0.01% less ownership
Funds ownership: 0.25% → 0.25% (-0.01%)
1% less capital invested
Capital invested by funds: $1.95M → $1.93M (-$22.3K)
15% less funds holding
Funds holding: 26 → 22 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
+$338K |
| 2 |
VF
Virtu Financial
New York
|
+$53.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.8K |
| 4 |
Citigroup
New York
|
+$140 |
| 5 |
Barclays
London,
United Kingdom
|
+$112 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$148K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$77K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$27K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$22K |
CARM Hedge Fund Activity: Q3 2017 in Review
22 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2017, worth a combined $1.93M — down 1.1% from $1.95M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CARM and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Municipal Employees' Retirement System of Michigan, opening a new position worth an estimated $338K. The largest seller was Spark Investment Management, exiting entirely with an estimated $148K sold.
- 22 institutional investors held Carisma Therapeutics (CARM) as of Q3 2017, down from 26 in Q2 2017.
- Funds reported $1.93M of Carisma Therapeutics stock for Q3 2017, down 1.1% quarter-over-quarter.
- 4 funds opened new Carisma Therapeutics positions in Q3 2017 and 7 closed out, a net change of -3 holders.
- The largest Carisma Therapeutics buyer in Q3 2017 was Municipal Employees' Retirement System of Michigan, an estimated $338K added.
- The largest Carisma Therapeutics seller in Q3 2017 was Spark Investment Management, an estimated $148K sold.
Based on aggregated 13F filings for Q3 2017.